• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Møller, P
    Evans, D Gareth R
    Haites, N
    Vasen, H
    Reis, Marta M
    Anderson, E
    Apold, J
    Hodgson, S
    Eccles, D
    Olsson, H
    Stoppa-Lyonnet, D
    Chang-Claude, J
    Morrison, P J
    Bevilacqua, G
    Heimdal, K
    Maehle, Lovise
    Lalloo, Fiona
    Gregory, H
    Preece, P
    Borg, A
    Nevin, N C
    Caligo, M
    Steel, C M
    Show allShow less
    Affiliation
    Unit of Medical Genetics, Norwegian Radium Hospital, Oslo, Norway. pmoller@ulrik.uio.no
    Issue Date
    1999-10
    
    Metadata
    Show full item record
    Citation
    Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. 1999, 15 (1-3):207-11 Dis. Markers
    Journal
    Disease markers
    URI
    http://hdl.handle.net/10541/87922
    PubMed ID
    10595280
    Type
    Article
    Language
    en
    ISSN
    0278-0240
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Familial breast and ovarian cancer: genetic counseling and clinical management in Italy.
    • Authors: Pasini B, Pierotti MA
    • Issue date: 1999 Oct
    • Molecular cancer genetics in eastern and central Europe.
    • Authors: Olah E
    • Issue date: 1999 Oct
    • Breast cancer genetics. Implications of clinical practice.
    • Authors: Olufunmilayo I, Olopade MD, Fackenthal JD
    • Issue date: 2000 Jun
    • Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
    • Authors: Chang-Claude J, Becher H, Caligo M, Eccles D, Evans G, Haites N, Hodgson S, Møller P, Weber BH, Stoppa-Lyonnet D
    • Issue date: 1999 Oct
    • The future of DNA diagnostics.
    • Authors: Critchfield GC
    • Issue date: 1999 Oct

    Related items

    Showing items related by title, author, creator and subject.

    • Thumbnail

      Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.

      O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
    • Thumbnail

      Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.

      Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)
      Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
    • Thumbnail

      AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.

      Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.